Interleukin-21 (IL-21) is a potent immunomodulatory cytokine, with pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects, such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer cells, and differentiation of B cells into plasma cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. IL-21 has potent antitumor activity, but is also associated with the development of autoimmune disease. Many of these activities are critically involved in the pathogenesis of several skin diseases such as psoriasis, atopic dermatitis, lupus erythematosus, and melanoma. Here we review recent advancements on the understanding of the role of IL-21 in skin diseases and how this knowledge can be translated into innovative therapeutic approaches.

Interleukin-21 (IL-21) is a potent immunomodulatory cytokine, with pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects, such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer cells, and differentiation of B cells into plasma cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. IL-21 has potent antitumor activity, but is also associated with the development of autoimmune disease. Many of these activities are critically involved in the pathogenesis of several skin diseases such as psoriasis, atopic dermatitis, lupus erythematosus, and melanoma. Here we review recent advancements on the understanding of the role of IL-21 in skin diseases and how this knowledge can be translated into innovative therapeutic approaches.

IL-21 in the pathogenesis and treatment of skin diseases.

A. Costanzo;
2010-01-01

Abstract

Interleukin-21 (IL-21) is a potent immunomodulatory cytokine, with pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects, such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer cells, and differentiation of B cells into plasma cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. IL-21 has potent antitumor activity, but is also associated with the development of autoimmune disease. Many of these activities are critically involved in the pathogenesis of several skin diseases such as psoriasis, atopic dermatitis, lupus erythematosus, and melanoma. Here we review recent advancements on the understanding of the role of IL-21 in skin diseases and how this knowledge can be translated into innovative therapeutic approaches.
2010
Interleukin-21 (IL-21) is a potent immunomodulatory cytokine, with pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects, such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8(+) T cells and natural killer cells, and differentiation of B cells into plasma cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. IL-21 has potent antitumor activity, but is also associated with the development of autoimmune disease. Many of these activities are critically involved in the pathogenesis of several skin diseases such as psoriasis, atopic dermatitis, lupus erythematosus, and melanoma. Here we review recent advancements on the understanding of the role of IL-21 in skin diseases and how this knowledge can be translated into innovative therapeutic approaches.
Animals, Autoimmune Diseases; immunology, Dermatitis; Atopic; immunology, Humans, Interleukins; immunology/therapeutic use, Melanoma; drug therapy, Mice, Skin Diseases; immunology, Skin Neoplasms; drug therapy
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/4236
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 28
social impact